Valuation: Gain Therapeutics, Inc.

Market Cap 80.3M 70.54M 66.23M 60.65M 113M 7.69B 114M 796M 308M 3.92B 302M 295M 12.71B P/E 2026 *
-3.77x
P/E 2027 * -2.82x
Enterprise Value 80.3M 70.54M 66.23M 60.65M 113M 7.69B 114M 796M 308M 3.92B 302M 295M 12.71B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.77%
Yield 2026 *
-
Yield 2027 * -
1 day-5.64%
1 week+7.60%
Current month+2.22%
1 month-8.23%
3 months-0.54%
6 months-5.64%
Current year-42.86%
1 week 1.74
Extreme 1.735
1.97
1 month 1.69
Extreme 1.69
2.05
Current year 1.53
Extreme 1.53
3.29
1 year 1.53
Extreme 1.53
4.34
3 years 0.89
Extreme 0.89
5.33
5 years 0.89
Extreme 0.89
9.7
10 years 0.89
Extreme 0.89
17.93
Manager TitleAgeSince
Chief Executive Officer 52 2024-06-24
Director of Finance/CFO 37 2025-01-05
Chief Tech/Sci/R&D Officer - 2024-03-24
Director TitleAgeSince
Chairman 69 2016-12-31
Director/Board Member 63 2019-04-30
Director/Board Member 58 2020-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Free

Director

25,000 0.0586%
7/15/26 Free

Founder

25,000 0.0586%
7/15/26 Free

Director

25,000 0.0586%
Change 5-day change 1-year change 3-year change Capi.($)
-5.64%+7.60%+5.75%-44.91% 85.11M
-0.18%+4.58%+3.88%+31.79% 47.86B
-0.83%-0.67%+42.61%+34.77% 44.46B
-0.84%+5.34%+8.05%+91.52% 41.85B
-1.10%-6.89%+329.50%+535.80% 41.34B
-0.62%-0.06%+10.15%+46.02% 30.04B
-2.07%-0.54%+23.90%+154.30% 17.59B
-6.08%-6.94% - - 15.6B
-3.55%+3.65%+21.51%+38.83% 15.69B
-0.78%+11.24%-10.81% - 13.93B
Average -1.99%+3.79%+48.28%+111.01% 26.84B
Weighted average by Cap. -1.07%+1.88%+67.04%+141.26%

Financials

2026 *2027 *
Net sales - -
Net income -21.57M -18.95M -17.79M -16.29M -30.41M -2.06B -30.64M -214M -82.83M -1.05B -80.98M -79.2M -3.41B -33.2M -29.17M -27.39M -25.08M -46.82M -3.18B -47.17M -329M -128M -1.62B -125M -122M -5.26B
Net Debt - -
Logo Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Employees
-
Date Price Change Volume
26-09-23 US$1.840 -5.64% 290,875
26-09-22 US$1.950 +5.98% 692,699
26-09-21 US$1.840 +4.55% 335,860
26-09-18 US$1.760 -1.12% 375,549
26-09-17 US$1.780 +3.49% 341,535
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.950USD
Average target price
7.200USD
Spread / Average Target
+269.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GANX Stock